S
Sigrid Carlsson
Researcher at University of Gothenburg
Publications - 60
Citations - 4447
Sigrid Carlsson is an academic researcher from University of Gothenburg. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 16, co-authored 21 publications receiving 4002 citations. Previous affiliations of Sigrid Carlsson include Memorial Sloan Kettering Cancer Center & Sahlgrenska University Hospital.
Papers
More filters
Journal ArticleDOI
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Teuvo L.J. Tammela,Marco Zappa,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Liisa Määttänen,Hans Lilja,Louis Denis,Franz Recker,Alvaro Paez,Chris H. Bangma,Sigrid Carlsson,Sigrid Carlsson,Donella Puliti,Arnauld Villers,Xavier Rebillard,Matti Hakama,Ulf-Håkan Stenman,Paula Kujala,Kimmo Taari,Gunnar Aus,Andreas R. Huber,Theo van der Kwast,Ron H.N. van Schaik,Harry J. de Koning,Sue Moss,Anssi Auvinen +29 more
TL;DR: In this update the ERSPC confirms a substantial reduction in prostate cancer mortality attributable to testing of PSA, with a substantially increased absolute effect at 13 years compared with findings after 9 and 11 years.
Journal ArticleDOI
Prostate-Cancer Mortality at 11 Years of Follow-up
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,Alvaro Paez,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Sigrid Carlsson,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Paula Kujala,Bert G. Blijenberg,Ulf-Håkan Stenman,Andreas R. Huber,Kimmo Taari,Matti Hakama,Sue Moss,Harry J. de Koning,Anssi Auvinen +27 more
TL;DR: Analyses after 2 additional years of follow-up consolidated the previous finding that PSA-based screening significantly reduced mortality from prostate cancer but did not affect all-cause mortality.
Journal ArticleDOI
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial
Jonas Hugosson,Sigrid Carlsson,Gunnar Aus,Svante Bergdahl,Ali Khatami,Pär Lodding,Carl-Gustaf Pihl,Johan Stranne,Erik Holmberg,Hans Lilja,Hans Lilja +10 more
TL;DR: It is shown that prostate cancer mortality was reduced almost by half over 14 years, however, the risk of over-diagnosis is substantial and the number needed to treat is at least as high as in breast-cancer screening programmes.
Journal ArticleDOI
Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)
Fritz H. Schröder,Jonas Hugosson,Sigrid Carlsson,Teuvo L.J. Tammela,Liisa Määttänen,Anssi Auvinen,Maciej Kwiatkowski,Franz Recker,Monique J. Roobol +8 more
TL;DR: PSA screening significantly reduces the risk of developing metastatic PCa, however, despite earlier diagnosis with screening, certain men still progress and develop metastases.
Journal ArticleDOI
Prostate Cancer Screening: Facts, Statistics, and Interpretation in Response to the US Preventive Services Task Force Review
Sigrid Carlsson,Andrew J. Vickers,Monique J. Roobol,James A. Eastham,Peter T. Scardino,Hans Lilja,Jonas Hugosson +6 more
TL;DR: Recently, the US Preventive Services Task Force (USPSTF) published a review of the evidence for screening for prostate cancer and made a clear recommendation against screening.